Akt1tm1Nhy/Akt1+
Akt2tm1Rsg/Akt2tm1Rsg
Ptentm1Ppp/Pten+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/1LacJ
|
enlarged pancreatic islets |
J:149156
|
|
impaired glucose tolerance |
J:149156
|
|
increased circulating insulin level |
J:149156
|
Akt2tm1.1Mbb/Akt2tm1.1Mbb
Ptentm1Hwu/Ptentm1Hwu
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA
|
abnormal liver morphology |
J:218587
|
|
decreased susceptibility to hepatic steatosis |
J:218587
|
|
hyperglycemia |
J:160759
|
|
impaired glucose tolerance |
J:160759
|
|
increased tumor latency |
J:218587
|
|
normal
liver/biliary system phenotype |
J:160759
|
Akt2tm1Rsg/Akt2tm1Rsg
Ptentm1Ppp/Pten+
involves: 129S1/Sv * C57BL/6 * DBA/1LacJ
|
decreased circulating insulin level |
J:149156
|
|
impaired glucose tolerance |
J:149156
|
Albtm1(cre/ERT2)Mtz/Alb+
Krastm4Tyj/Kras+
Ptentm2Mak/Ptentm2Mak
involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae
|
increased cholangiocarcinoma incidence |
J:254370
|
|
increased hepatocellular carcinoma incidence |
J:254370
|
Amhr2tm3(cre)Bhr/Amhr2+
Ctnnb1tm1Mmt/Ctnnb1+
Ptentm1Hwu/Ptentm1Hwu
involves: 129S4/SvJae * 129S7/SvEvBrd * 129X1/SvJ
|
anemia |
J:142150
|
|
decreased hematocrit |
J:142150
|
|
extramedullary hematopoiesis |
J:142150
|
|
increased granulosa cell tumor incidence |
J:149060
|
|
increased metastatic potential |
J:142150,
J:149060
|
|
increased ovary tumor incidence |
J:142150
|
|
increased testis tumor incidence |
J:149060
|
|
premature death |
J:142150
|
|
pulmonary embolism |
J:142150
|
|
seminiferous tubule degeneration |
J:149060
|
Amhr2tm3(cre)Bhr/Amhr2+
Ctnnb1tm1Mmt/Ctnnb1+
Ptentm1Hwu/Ptentm1Hwu
involves: 129S4/SvJae * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6
|
increased granulosa cell tumor incidence |
J:186144
|
|
increased testis tumor incidence |
J:186144
|
ApcMin/Apc+
Ptentm1Hwu/Ptentm1Hwu
Tg(Vil1-cre)997Gum/0
involves: 129S4/SvJae * BALB/c * C57BL/6J * SJL
|
increased intestinal adenoma incidence |
J:150553
|
|
intestine polyps |
J:150553
|
|
premature death |
J:150553
|
Apctm1Tno/Apc+
Ptentm2Mak/Ptentm2Mak
Tg(Cyp1a1-cre/ERT)1Dwi/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA
|
abnormal small intestine morphology |
J:143082
|
|
increased intestinal adenocarcinoma incidence |
J:143082
|
|
peritoneal inflammation |
J:143082
|
|
premature death |
J:143082
|
Apctm1Tno/Apctm1Tno
Ptentm1Hwu/Ptentm1Hwu
Tg(Cyp1a1-cre/ERT)1Dwi/0
involves: 129S4/SvJae * C57BL/6 * CBA
|
abnormal urinary bladder urothelium morphology |
J:164579
|
Apctm1Tno/Apctm1Tno
Ptentm2Mak/Ptentm2Mak
involves: 129P2/OlaHsd * 129S4/SvJae
|
decreased tumor-free survival time |
J:120955
|
|
hemorrhagic ascites |
J:120955
|
|
increased ovarian carcinoma incidence |
J:120955
|
Artm1Verh/Y
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2
|
increased prostate gland adenocarcinoma incidence |
J:172730
|
Bcl2l11tm1.1Ast/Bcl2l11+
Ptentm1Hwu/Pten+
Tg(CD2-icre)4Kio/0
involves: 129S1/Sv * 129S4/SvJae * C57BL/10 * CBA/Ca
|
abnormal T cell number |
J:133215
|
|
increased germinal center B cell number |
J:133215
|
Braftm1Mmcm/Braf+
Ptentm1Mro/Ptentm1Mro
Tg(Tyr-cre/ERT2)1Lru/0
B6.Cg-Braftm1Mmcm Tg(Tyr-cre/ERT2)1Lru Ptentm1Mro
|
decreased tumor-free survival time |
J:188523
|
|
increased cutaneous melanoma incidence |
J:188523
|
|
premature death |
J:188523
|
|
spontaneous skin ulceration |
J:188523
|
Braftm1Mmcm/Braf+
Ptentm2.1Ppp/Pten+
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * 129S1/Sv * FVB
|
abnormal melanocyte morphology |
J:151023
|
|
increased cutaneous melanoma incidence |
J:151023
|
Braftm1Mmcm/Braf+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * 129S1/Sv * FVB
|
increased cutaneous melanoma incidence |
J:151023
|
|
increased metastatic potential |
J:151023
|
Braftm1Mmcm/Braf+
Ptentm1Rdp/Ptentm1Rdp
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N
|
increased cutaneous melanoma incidence |
J:151023
|
|
increased metastatic potential |
J:151023
|
Braftm1Mmcm/Braftm1Mmcm
Nkx3-1tm4(cre/ERT2)Mms/Nkx3-1+
Ptentm1Hwu/Pten+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6
|
increased metastatic potential |
J:191327
|
|
increased prostate gland adenocarcinoma incidence |
J:191327
|
|
increased prostate gland tumor incidence |
J:191327
|
|
increased prostate intraepithelial neoplasia incidence |
J:191327
|
|
premature death |
J:191327
|
Calcatm1.1(cre/ERT2)Ptch/Calca+
Trp53tm1Brn/Trp53tm1Brn
Rb1tm2Brn/Rb1tm2Brn
Ptentm1Hwu/Ptentm1Hwu
involves: 129 * 129P2/OlaHsd * 129S4/SvJae * BALB/c * FVB/N
|
abnormal pulmonary neuroendocrine body morphology |
J:190366
|
|
increased lung small cell carcinoma incidence |
J:190366
|
|
increased metastatic potential |
J:190366
|
|
increased thyroid tumor incidence |
J:190366
|
|
postnatal lethality |
J:190366
|
Cd19tm1(cre)Cgn/Cd19+
Ptentm1Hwu/Ptentm1Hwu
Tg(IghelMD4)4Ccg/0
Tg(ML5sHEL)5Ccg/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
abnormal peripheral B cell anergy |
J:155314
|
Cd19tm1(cre)Cgn/Cd19+
Inpp5dtm1Rav/Inpp5dtm1Rav
Ptentm1Hwu/Ptentm1Hwu
involves: 129P2/OlaHsd * 129S4/SvJae
|
abnormal B cell morphology |
J:166155
|
|
abnormal B cell physiology |
J:166155
|
|
abnormal coat appearance |
J:166155
|
|
abnormal myeloid leukocyte morphology |
J:166155
|
|
decreased B cell number |
J:166155
|
|
enlarged spleen |
J:166155
|
|
hunched posture |
J:166155
|
|
increased B cell number |
J:166155
|
|
increased B cell proliferation |
J:166155
|
|
increased follicular lymphoma incidence |
J:166155
|
|
increased lymphoma incidence |
J:166155
|
|
increased malignant tumor incidence |
J:166155
|
|
increased plasmacytoma incidence |
J:166155
|
|
increased spleen white pulp amount |
J:166155
|
|
increased splenic marginal zone lymphoma incidence |
J:166155
|
|
lethargy |
J:166155
|
|
premature death |
J:166155
|
|
weight loss |
J:166155
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj
Ptentm1Hwu/Ptentm1Hwu
Tg(Fabp1-cre)1Jig/0
involves: 129S2/SvPas * 129S4/SvJae * FVB/N
|
abnormal urinary bladder urothelium morphology |
J:106662
|
|
increased urinary bladder carcinoma incidence |
J:106662
|
Cdkn1btm1Ako/Cdkn1b+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(TPO-cre)1Shk/0
129S1.Cg-Cdkn1btm1Ako Tg(TPO-cre)1Shk Ptentm2.1Ppp
|
increased thyroid adenoma incidence |
J:165293
|
|
increased thyroid carcinoma incidence |
J:165293
|
|
premature death |
J:165293
|
Cdkn1btm1Ako/Cdkn1btm1Ako
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(TPO-cre)1Shk/0
129S1.Cg-Cdkn1btm1Ako Tg(TPO-cre)1Shk Ptentm2.1Ppp
|
premature death |
J:165293
|
|
respiratory distress |
J:165293
|
|
thyroid gland hyperplasia |
J:165293
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Col1a1tm1(CAG-EGFR)Char/Col1a1tm1(CAG-EGFR)Char
Ptentm1Hwu/Ptentm1Hwu
involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL
|
decreased tumor-free survival time |
J:146494
|
|
increased glioblastoma incidence |
J:146494
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Col1a1tm1(CAG-EGFR)Char/Col1a1tm2(CAG-EGFR*)Char
Ptentm1Hwu/Ptentm1Hwu
involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL
|
decreased tumor-free survival time |
J:146494
|
|
increased glioblastoma incidence |
J:146494
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Col1a1tm2(CAG-EGFR*)Char/Col1a1tm2(CAG-EGFR*)Char
Ptentm1Hwu/Ptentm1Hwu
involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL
|
decreased tumor-free survival time |
J:146494
|
|
increased glioblastoma incidence |
J:146494
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt
Ptentm1Rps/Ptentm1Rps
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129/Sv * C57BL/6J * FVB * SJL
|
increased melanoma incidence |
J:155731
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptentm1Rdp/Ptentm1Rdp
Tg(tetO-BRAF*V600E)29Lc/0
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129/Sv * C57BL/6J * FVB * SJL
|
increased melanoma incidence |
J:221902
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Ptentm1Rps/Ptentm1Rps
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129/Sv * 129S1/Sv * C57BL/6J * FVB/N * SJL
|
increased melanoma incidence |
J:155731
|
Coro1ctm1c(KOMP)Wtsi/Coro1ctm1c(KOMP)Wtsi
Ptentm2Mak/Ptentm2Mak
Trp53tm1Brn/Trp53tm1Brn
Tg(GFAP-cre/Esr1*,-lacZ)ASbk/0
involves: 129P2/OlaHsd * C57BL/6N * FVB/NJ
|
increased glioblastoma incidence |
J:290447
|
|
premature death |
J:290447
|
Ctnnb1tm1Mmt/Ctnnb1+
Ptentm1Hwu/Ptentm1Hwu
Tg(CYP19A1-cre)1Jri/0
involves: 129S4/SvJae * 129X1/SvJ * C57BL/6
|
decreased circulating estradiol level |
J:186144
|
|
decreased circulating progesterone level |
J:186144
|
|
decreased granulosa cell apoptosis |
J:186144
|
|
decreased tumor-free survival time |
J:186144
|
|
impaired granulosa cell differentiation |
J:186144
|
|
increased circulating follicle stimulating hormone level |
J:186144
|
|
increased circulating luteinizing hormone level |
J:186144
|
|
increased granulosa cell proliferation |
J:186144
|
|
increased granulosa cell tumor incidence |
J:186144
|
|
increased ovary tumor incidence |
J:186144
|
Ctnnb1tm1Mmt/Ctnnb1+
Ptentm1Hwu/Ptentm1Hwu
Tg(Upk2-cre)6Xrw/0
involves: 129S4/SvJae * 129X1/SvJ * FVB/N
|
increased urinary bladder carcinoma incidence |
J:164579
|
|
premature death |
J:164579
|
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt
Ptentm1Hwu/Ptentm1Hwu
Tg(Upk2-cre)6Xrw/0
involves: 129S4/SvJae * 129X1/SvJ * FVB/N
|
increased urinary bladder carcinoma incidence |
J:164579
|
|
premature death |
J:164579
|
Ctnnb1tm2Kem/Ctnnb1+
Ptentm1Hwu/Ptentm1Hwu
Tg(Cdh5-cre)7Mlia/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/c * C57BL/6 * FVB/N
|
abnormal blood vessel morphology |
J:135172
|
|
abnormal definitive hematopoiesis |
J:135172
|
|
premature death |
J:135172
|
Ctnnb1tm2Kem/Ctnnb1tm2Kem
Ptentm1Hwu/Ptentm1Hwu
Tg(Cdh5-cre)7Mlia/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/c * C57BL/6 * FVB/N
|
embryonic lethality, complete penetrance |
J:135172
|
Del(16Tmprss2-Erg)1Sho/Del(16Tmprss2-Erg)1Sho
Ptentm1.1Hwu/Pten+
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
increased prostate intraepithelial neoplasia incidence |
J:212219
|
Dicer1tm1Tara/Dicer1tm1Tara
Ptentm1Hwu/Ptentm1Hwu
Amhr2tm3(cre)Bhr/Amhr2+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd
|
abnormal oviduct morphology |
J:182161
|
|
ascites |
J:182161
|
|
increased carcinoma incidence |
J:182161
|
|
increased metastatic potential |
J:182161
|
|
increased ovarian carcinoma incidence |
J:182161
|
|
premature death |
J:182161
|
Dicer1tm1Tara/Dicer1tm1Tara
Ptentm1Hwu/Ptentm1Hwu
Trp53tm2Tyj/Trp53+
Amhr2tm3(cre)Bhr/Amhr2+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd
|
ascites |
J:222579
|
|
increased carcinoma incidence |
J:222579
|
|
increased metastatic potential |
J:222579
|
|
increased ovarian carcinoma incidence |
J:222579
|
|
premature death |
J:222579
|
Eif2ak3tm1.2Drc/Eif2ak3tm1.2Drc
Ptentm1Hwu/Ptentm1Hwu
Tg(CAG-MYC,-GFP*)#Rugg/0
Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2
|
decreased prostate gland tumor incidence |
J:261540
|
Eif4etm1.1Lfur/Eif4etm1.1Lfur
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2
|
decreased tumor incidence |
J:163589
|
Erbb2tm8(Erbb2)Mul/Erbb2+
Ptentm1Hwu/Pten+
Tg(MMTV-cre)7Mul/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * FVB/N
|
increased mammary gland tumor incidence |
J:133305
|
|
increased metastatic potential |
J:133305
|
Erbb2tm8(Erbb2)Mul/Erbb2+
Ptentm1Hwu/Ptentm1Hwu
Tg(MMTV-cre)7Mul/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * FVB/N
|
increased mammary gland tumor incidence |
J:133305
|
Ergtm1.1Sho/Ergtm1.1Sho
Ptentm1Hwu/Ptentm1Hwu
Tmprss2tm3Sho/Tmprss2tm3Sho
Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
increased prostate gland adenocarcinoma incidence |
J:212219
|
|
normal
mortality/aging |
J:212219
|
Errfi1tm1Jwj/Errfi1tm1Jwj
Pgrtm2(cre)Lyd/Pgr+
Ptentm1Hwu/Ptentm1Hwu
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ
|
abnormal endometrium morphology |
J:162027
|
|
endometrium hyperplasia |
J:162027
|
|
increased endometrial carcinoma incidence |
J:162027
|
|
increased metastatic potential |
J:162027
|
|
increased uterus weight |
J:162027
|
|
premature death |
J:162027
|
Ets2tm1Rgo/Ets2tm5.1Rgo
Ptentm1.1Mwst/Ptentm1.1Mwst
Tg(S100a4-cre)1Gle/0
involves: 129S2/SvPas * FVB/N
|
abnormal tumor morphology |
J:153747
|
|
decreased mammary gland tumor incidence |
J:153747
|
|
increased mammary gland tumor incidence |
J:153747
|
Fastm1Ach/Fastm1Ach
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
involves: 129S4/SvJae
|
decreased ovarian tumor incidence |
J:161953
|
Foxo1tm1Rdp/Foxo1tm1.1Rdp
Foxo3tm1Rdp/Foxo3tm1.1Rdp
Ptentm1Hwu/Ptentm1Hwu
Tg(CYP19A1-cre)1Jri/0
involves: 129S4/SvJae * 129S6/SvEvTac
|
abnormal circulating hormone level |
J:232961
|
|
decreased circulating luteinizing hormone level |
J:232961
|
|
increased granulosa cell tumor incidence |
J:232961
|
|
suppressed circulating follicle stimulating hormone level |
J:232961
|
Grb2tm1Paw/Grb2+
Ptentm1Mak/Pten+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6
|
increased adrenal gland tumor incidence |
J:93530
|
|
increased endometrial carcinoma incidence |
J:93530
|
|
increased lymphoma incidence |
J:93530
|
|
increased tumor incidence |
J:93530
|
|
normal
mortality/aging |
J:93530
|
Grb2tm1Paw/Grb2+
Ptentm2Mak/Ptentm2Mak
Tg(Lck-cre)548Jxm/0
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
increased T cell derived lymphoma incidence |
J:93530
|
Grhl3tm1Jane/Grhl3+
Ptentm1Mak/Pten+
involves: 129P2/OlaHsd * 129S1/Sv
|
increased skin papilloma incidence |
J:178952
|
|
increased skin squamous cell carcinoma incidence |
J:178952
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Ptentm1Mro/Pten+
Tg(Pbsn-cre)4Prb/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N
|
increased prostate gland adenocarcinoma incidence |
J:184533
|
|
increased prostate intraepithelial neoplasia incidence |
J:184533
|
|
urinary bladder obstruction |
J:184533
|
Gt(ROSA)26Sortm1(CAG-Errfi1)Jwj/?
Pgrtm2(cre)Lyd/Pgr+
Ptentm1Hwu/Ptentm1Hwu
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
|
abnormal uterus physiology |
J:218222
|
|
endometrium hyperplasia |
J:218222
|
|
increased papilloma incidence |
J:218222
|
|
increased uterus weight |
J:218222
|
|
premature death |
J:218222
|
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Ptentm2.1Ppp
Rb1tm2Brn/Rb1+
Tg(Pbsn-cre)4Prb/0
involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2
|
increased prostate gland tumor incidence |
J:307910
|
|
premature death |
J:307910
|
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Ptentm2.1Ppp
Rb1tm2Brn/Rb1tm2Brn
Tg(Pbsn-cre)4Prb/0
involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2
|
increased metastatic potential |
J:307910
|
|
increased prostate gland tumor incidence |
J:307910
|
|
premature death |
J:307910
|
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)4Prb/0
involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2
|
increased prostate intraepithelial neoplasia incidence |
J:307910
|
|
premature death |
J:307910
|
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
abnormal prostate gland physiology |
J:170965
|
|
enlarged prostate gland anterior lobe |
J:170965
|
|
increased prostate gland tumor incidence |
J:170965
|
|
increased prostate gland weight |
J:170965
|
|
prostate gland hyperplasia |
J:170965
|
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor+
Ptentm1.1Hwu/Pten+
involves: 129S4/SvJae * C57BL/6NTac
|
increased lymphoma incidence |
J:170965
|
|
increased thyroid adenoma incidence |
J:170965
|
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sortm9(cre/ESR1)Arte
Ptentm1Hwu/Ptentm1Hwu
involves: 129S4/SvJae * C57BL/6
|
decreased B cell number |
J:170965
|
|
disheveled coat |
J:170965
|
|
enlarged lymph nodes |
J:170965
|
|
enlarged spleen |
J:170965
|
|
hunched posture |
J:170965
|
|
increased acute lymphoblastic leukemia incidence |
J:170965
|
|
increased memory B cell number |
J:170965
|
|
increased spleen weight |
J:170965
|
|
premature death |
J:170965
|
|
weight loss |
J:170965
|
Gt(ROSA)26Sortm1(JAG1)Xin/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)20Fwan/?
involves: 129S4/SvJae * C57BL/6 * FVB/NCrl
|
abnormal prostate gland morphology |
J:238768
|
|
increased prostate gland adenocarcinoma incidence |
J:238768
|
|
increased prostate intraepithelial neoplasia incidence |
J:238768
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tg(Adipoq-cre)1Evdr/0
involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6J * FVB/NJ
|
abnormal brown adipose tissue morphology |
J:237232
|
|
normal
homeostasis/metabolism phenotype |
J:237232
|
|
increased liposarcoma incidence |
J:237232
|
|
lipodystrophy |
J:237232
|
Gt(ROSA)26Sortm1(SPOP*F133V)Mrbn/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Pten+
Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * C57BL/6 * DBA/2
|
increased prostate gland adenocarcinoma incidence |
J:239660
|
|
increased prostate intraepithelial neoplasia incidence |
J:239660
|
Gt(ROSA)26Sortm1(SPOP*F133V)Mrbn/Gt(ROSA)26Sor+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * C57BL/6 * DBA/2
|
increased prostate gland adenocarcinoma incidence |
J:239660
|
Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key/Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * C57BL/6 * DBA/2
|
abnormal prostate gland physiology |
J:200002
|
|
distended abdomen |
J:200002
|
|
enlarged prostate gland |
J:200002
|
|
increased prostate gland adenocarcinoma incidence |
J:200002
|
|
increased prostate intraepithelial neoplasia incidence |
J:200002
|
|
penis prolapse |
J:200002
|
|
premature death |
J:200002
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Rb1tm2Brn/Rb1tm2Brn
involves: 129 * 129S4/SvJaeSor * C57BL/6 * FVB
|
normal
neoplasm |
J:204385
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
involves: 129 * 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N
|
increased nervous system tumor incidence |
J:204385
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Slc1a3tm1(cre/ERT2)Mgoe/Slc1a3+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJaeSor
|
increased astrocytoma incidence |
J:229481
|
|
increased glioma incidence |
J:229481
|
|
increased oligodendroglioma incidence |
J:229481
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJaeSor
|
increased astrocytoma incidence |
J:229481
|
|
increased glioma incidence |
J:229481
|
|
increased oligodendroglioma incidence |
J:229481
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB
|
increased astrocytoma incidence |
J:204385
|
|
increased glioma incidence |
J:204385
|
|
increased oligodendroglioma incidence |
J:204385
|
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Ptentm2Mak/Ptentm2Mak
Tg(RasE)290Biat/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
increased lung tumor incidence |
J:226601
|
|
increased pancreas tumor incidence |
J:226601
|
|
premature death |
J:226601
|
Gt(ROSA)26Sortm2(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
enlarged prostate gland anterior lobe |
J:170965
|
|
increased prostate gland tumor incidence |
J:170965
|
|
increased prostate gland weight |
J:170965
|
|
prostate gland hyperplasia |
J:170965
|
Gt(ROSA)26Sortm2Thl/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Trp53tm1Thl/Trp53tm1Thl
Tyrc-Brd/Tyrc-Brd
involves: 129/Sv * 129S4/SvJae * C57BL/6
|
increased glioblastoma incidence |
J:172585
|
|
increased tumor growth/size |
J:172585
|
|
premature death |
J:172585
|
Gt(ROSA)26Sortm2Thl/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Tyrc-Brd/Tyrc-Brd
involves: 129/Sv * 129S4/SvJae * C57BL/6
|
increased glioblastoma incidence |
J:172585
|
|
premature death |
J:172585
|
Hrastm1Jaf/Hrastm1Jaf
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(TPO-cre)1Shk/0
involves: 129S1/Sv * 129S6/SvEvTac * FVB/NCr
|
increased thyroid tumor incidence |
J:231492
|
Hspa5tm1Alee/Hspa5+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/?
involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2
|
increased prostate gland adenocarcinoma incidence |
J:142106
|
|
increased prostate intraepithelial neoplasia incidence |
J:142106
|
Hspa5tm1Alee/Hspa5tm1.1Alee
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/?
involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2
|
normal
neoplasm |
J:142106
|
Hspa5tm1Alee/Hspa5tm1Alee
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/?
involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2
|
normal
neoplasm |
J:142106
|
Igs2tm1(CAG-Met)Zsu/Igs2+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
involves: 129 * C57BL/6 * DBA/2 * FVB/N
|
increased carcinoma incidence |
J:268934
|
|
increased metastatic potential |
J:268934
|
|
increased prostate gland adenocarcinoma incidence |
J:268934
|
|
increased prostate gland tumor incidence |
J:268934
|
|
increased prostate intraepithelial neoplasia incidence |
J:268934
|
Kdrtm1Jrt/Kdr+
Ptentm1Hwu/Ptentm1Hwu
Twist2tm1.1(cre)Dor/Twist2+
B6.129-Twist2tm1.1(cre)Dor Kdrtm1Jrt Ptentm1Hwu
|
abnormal lung morphology |
J:192736
|
|
abnormal vasculogenesis |
J:192736
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Pten+
Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
increased metastatic potential |
J:184935
|
|
increased prostate gland adenocarcinoma incidence |
J:184935
|
|
premature death |
J:184935
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Pten+
Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * BALB/c * C57BL/6
|
increased pancreas tumor incidence |
J:164210
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:164210
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:164210
|
|
pancreatic acinar-to-ductal metaplasia |
J:164210
|
|
premature death |
J:164210
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Pten+
Tg(Upk2-cre)6Xrw/0
involves: 129S4/SvJae * FVB/N
|
increased skin papilloma incidence |
J:174242
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Pten+
Tg(Gfap-cre)77.6Mvs/0
involves: 129S4/SvJae * BALB/c * C57BL/6NHsd
|
increased classified tumor incidence |
J:154673
|
|
increased neurofibroma incidence |
J:154673
|
|
increased neurofibrosarcoma incidence |
J:154673
|
|
premature death |
J:154673
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
involves: 129S4/SvJae
|
increased ovary tumor incidence |
J:161953
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
involves: 129S4/SvJae * C57BL/6J
|
increased endometrial carcinoma incidence |
J:96296
|
|
increased metastatic potential |
J:96296
|
|
premature death |
J:96296
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
Scgb1a1tm1.1(cre)Fjd/Scgb1a1+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ
|
increased lung adenocarcinoma incidence |
J:131721
|
|
increased lung adenoma incidence |
J:131721
|
|
increased lung carcinoma incidence |
J:131721
|
|
increased lung tumor incidence |
J:131721
|
|
lung inflammation |
J:131721
|
|
premature death |
J:131721
|
|
tachypnea |
J:131721
|
|
weight loss |
J:131721
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
abnormal prostate gland morphology |
J:184935
|
|
increased metastatic potential |
J:184935
|
|
increased prostate gland adenocarcinoma incidence |
J:184935
|
|
premature death |
J:184935
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA
|
abnormal exocrine pancreas morphology |
J:164210
|
|
edema |
J:164210
|
|
exocrine pancreas atrophy |
J:164210
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:164210
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:164210
|
|
pancreatic acinar-to-ductal metaplasia |
J:164210
|
|
postnatal lethality, complete penetrance |
J:164210
|
Krastm4Tyj/Kras+
Ptentm1Hwu/Ptentm1Hwu
Tg(Scgb1a1-cre)1Tauc/0
involves: 129S4/SvJae * C57BL/6
|
abnormal bronchiole morphology |
J:136369
|
|
abnormal bronchus morphology |
J:136369
|
Krastm4Tyj/Kras+
Ptentm2Mak/Pten+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA
|
increased cholangiocarcinoma incidence |
J:254370
|
|
increased hepatocellular carcinoma incidence |
J:254370
|
|
increased liver tumor incidence |
J:254370
|
Krastm4Tyj/Kras+
Ptentm2Mak/Ptentm2Mak
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA
|
bile duct hyperplasia |
J:254370
|
|
distended abdomen |
J:254370
|
|
enlarged liver |
J:254370
|
|
hemorrhagic ascites |
J:254370
|
|
increased cholangiocarcinoma incidence |
J:254370
|
|
increased liver tumor incidence |
J:254370
|
|
jaundice |
J:254370
|
|
postnatal growth retardation |
J:254370
|
|
premature death |
J:254370
|
|
weight loss |
J:254370
|
Krastm4Tyj/Kras+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(TPO-cre)1Shk/0
129.Cg-Krastm4Tyj Tg(Tpo-cre)1Shk Ptentm2.1Ppp
|
decreased circulating thyroid-stimulating hormone level |
J:147732
|
|
enlarged thyroid gland |
J:147732
|
|
increased metastatic potential |
J:147732
|
|
increased thyroid carcinoma incidence |
J:147732
|
|
increased thyroxine level |
J:147732
|
|
premature death |
J:147732
|
Krastm4Tyj/Kras+
Krt19tm1(cre/ERT)Ggu/Krt19+
Ptentm2Mak/Ptentm2Mak
involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac
|
abnormal colon morphology |
J:254370
|
|
abnormal cystic duct morphology |
J:254370
|
|
abnormal extrahepatic bile duct morphology |
J:254370
|
|
abnormal gallbladder morphology |
J:254370
|
|
abnormal liver morphology |
J:254370
|
|
bronchial epithelial hyperplasia |
J:254370
|
|
dilated gallbladder |
J:254370
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:254370
|
|
lung inflammation |
J:254370
|
|
premature death |
J:254370
|
|
respiratory failure |
J:254370
|
|
stomach mucosa hyperplasia |
J:254370
|
Leprdb/Leprdb
Ptentm1Hwu/Ptentm1Hwu
Tg(Ins2-cre)25Mgn/0
involves: 129S4/SvJae * C57BL/6 * C57BLKS/J * DBA
|
abnormal pancreatic islet morphology |
J:170206
|
|
normal
homeostasis/metabolism phenotype |
J:170206
|
|
increased body weight |
J:170206
|
|
increased insulin secretion |
J:170206
|
|
insulin resistance |
J:170206
|
Mirc14tm1.1Flv/Mirc14tm1.1Flv
Ptentm1Hwu/Ptentm1Hwu
Tg(Cd4-cre)1Cwi/0
involves: 129S4/SvJae * C57BL/6 * C57BL/6N * DBA/2 * SJL
|
normal
immune system phenotype |
J:203157
|
Mlst8tm1Lex/Mlst8+
Ptentm1Rps/Pten+
involves: 129S1/Sv * 129S5/SvEvBrd * C57BL/6
|
extended life span |
J:144810
|
MtorGt(OST92090)Lex/Mtor+
Ptentm1Rps/Pten+
involves: 129S1/Sv * 129S5/SvEvBrd * C57BL/6
|
extended life span |
J:144810
|
Nf1tm1Fcr/Nf1+
Ptentm1Hwu/Ptentm1Hwu
Tg(Mx1-cre)1Cgn/0
B6.Cg-Tg(Mx1-cre)1Cgn Nf1tm1Fcr Ptentm1Hwu
|
abnormal bone marrow morphology |
J:232645
|
|
abnormal hematopoietic stem cell morphology |
J:232645
|
|
abnormal hemopoiesis |
J:232645
|
|
abnormal liver morphology |
J:232645
|
|
abnormal lung morphology |
J:232645
|
|
abnormal spleen morphology |
J:232645
|
|
anemia |
J:232645
|
|
decreased B cell number |
J:232645
|
|
decreased bone marrow cell number |
J:232645
|
|
decreased hemoglobin content |
J:232645
|
|
decreased lymphocyte cell number |
J:232645
|
|
decreased T cell number |
J:232645
|
|
enlarged liver |
J:232645
|
|
enlarged spleen |
J:232645
|
|
increased granulocyte number |
J:232645
|
|
increased leukocyte cell number |
J:232645
|
|
increased liver weight |
J:232645
|
|
increased macrophage cell number |
J:232645
|
|
increased monocyte cell number |
J:232645
|
|
increased spleen weight |
J:232645
|
|
increased T cell acute lymphoblastic leukemia incidence |
J:232645
|
|
increased tumor incidence |
J:232645
|
|
premature death |
J:232645
|
|
thrombocytosis |
J:232645
|
Nf1tm1Par/Nf1+
Ptentm1Hwu/Pten+
Trp53tm1Tyj/Trp53+
Tg(GFAP-cre)25Mes/0
involves: 129S1/Sv * 129S2/SvPas * 129S4/SvJae * 129X1/SvJ * FVB/N
|
ataxia |
J:134611
|
|
increased astrocytoma incidence |
J:134611
|
|
increased brain tumor incidence |
J:134611
|
|
increased startle reflex |
J:134611
|
|
premature death |
J:134611
|
|
seizures |
J:134611
|
|
unidirectional circling |
J:134611
|
Nf1tm1Par/Nf1+
Ptentm1Hwu/Pten+
Trp53tm1Elee/Trp53+
Tg(GFAP-cre)25Mes/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * FVB/N
|
ataxia |
J:134611
|
|
increased astrocytoma incidence |
J:134611
|
|
increased brain tumor incidence |
J:134611
|
|
increased startle reflex |
J:134611
|
|
premature death |
J:134611
|
|
seizures |
J:134611
|
|
unidirectional circling |
J:134611
|
Nf1tm1Par/Nf1+
Ptentm1Hwu/Pten+
Tg(Gfap-cre)77.6Mvs/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/c * C57BL/6NHsd
|
normal
neoplasm |
J:154673
|
Nkx3-1tm1Mms/Nkx3-1+
Ptentm1Rps/Pten+
involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J
|
increased prostate gland tumor incidence |
J:75085
|
|
increased prostate intraepithelial neoplasia incidence |
J:75085
|
Nkx3-1tm1Mms/Nkx3-1tm1Mms
Ptentm1Rps/Pten+
involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J
|
increased prostate gland tumor incidence |
J:75085
|
|
increased prostate intraepithelial neoplasia incidence |
J:75085
|
Pdpk1tm1Maka/Pdpk1tm1Maka
Ptentm1Hwu/Ptentm1Hwu
Tg(Zp3-cre)93Knw/0
involves: 129S4/SvJae * C57BL/6J
|
normal
reproductive system phenotype |
J:165798
|
Pgrtm2(cre)Lyd/Pgr+
Ptentm1Hwu/Ptentm1Hwu
Trp53tm1Brn/Trp53tm1Brn
involves: 129 * C57BL/6
|
endometrium hyperplasia |
J:139053
|
|
enlarged uterus |
J:139053
|
|
increased endometrial carcinoma incidence |
J:139053
|
|
premature death |
J:139053
|
Pik3catm1.1Waph/Pik3ca+
Ptentm1Hwu/Ptentm1Hwu
involves: 129S1/Sv * 129S4/SvJae * BALB/c * C57BL/6
|
abnormal diaphragm morphology |
J:184382
|
|
abnormal ovary morphology |
J:184382
|
|
abnormal ovary physiology |
J:184382
|
|
abnormal peritoneum morphology |
J:184382
|
|
hemorrhagic ascites |
J:184382
|
|
increased adenocarcinoma incidence |
J:184382
|
|
increased granulosa cell tumor incidence |
J:184382
|
|
increased ovary tumor incidence |
J:184382
|
|
ovary hemorrhage |
J:184382
|
|
premature death |
J:184382
|
Pik3catm1Jjz/Pik3catm1Jjz
Pik3cbtm1Jjz/Pik3cbtm1Jjz
Ptentm1Hwu/Ptentm1Hwu
Tg(KRT14-cre)#Smr/0
FVB.Cg-Pik3catm1Jjz Pik3cbtm1Jjz Ptentm1Hwu Tg(KRT14-cre)#Smr
|
normal
integument phenotype |
J:199362
|
Pik3catm1Jjz/Pik3catm1Jjz
Ptentm1Hwu/Ptentm1Hwu
Tg(KRT14-cre)#Smr/0
FVB.Cg-Pik3catm1Jjz Ptentm1Hwu Tg(KRT14-cre)#Smr
|
increased skin hamartoma incidence |
J:199362
|
|
skin lesions |
J:199362
|
|
thick epidermis stratum basale |
J:199362
|
|
thick skin |
J:199362
|
Pik3cbtm1Jjz/Pik3cbtm1Jjz
Ptentm1Hwu/Ptentm1Hwu
Tg(KRT14-cre)#Smr/0
FVB.Cg-Pik3cbtm1Jjz Ptentm1Hwu Tg(KRT14-cre)#Smr
|
abnormal epidermis suprabasal layer morphology |
J:199362
|
|
increased skin hamartoma incidence |
J:199362
|
|
skin lesions |
J:199362
|
|
thick skin |
J:199362
|
Pik3cdtm1Tnr/Pik3cdtm1Tnr
Ptentm2.1Ppp/Ptentm2.1Ppp
Cd19tm1(cre)Cgn/Cd19+
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJae * C57BL/6
|
abnormal class switch recombination |
J:130950
|
|
normal
immune system phenotype |
J:130950
|
|
increased marginal zone B cell number |
J:130950
|
Pik3cgtm1Pngr/Pik3cgtm1Pngr
Ptentm2Mak/Ptentm2Mak
Tg(Ckmm-cre)5Khn/0
involves: 129P2/OlaHsd * FVB
|
cardiac hypertrophy |
J:79151
|
|
enlarged heart |
J:79151
|
|
increased cardiac muscle contractility |
J:79151
|
Pkn3tm1.1Mrl/Pkn3+
Ptentm1Hwu/Ptentm1Hwu
Tg(Mx1-cre)1Cgn/0
involves: 129S4/SvJae * C57BL/6 * CBA/J
|
enlarged spleen |
J:216983
|
|
enlarged thymus |
J:216983
|
|
extramedullary hematopoiesis |
J:216983
|
|
increased acute lymphoblastic leukemia incidence |
J:216983
|
|
increased hemolymphoid system tumor incidence |
J:216983
|
|
premature death |
J:216983
|
Pkn3tm1.1Mrl/Pkn3tm1.1Mrl
Ptentm1Hwu/Ptentm1Hwu
Tg(CD2-icre)4Kio/0
involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca
|
normal
endocrine/exocrine gland phenotype |
J:216983
|
Pkn3tm1.1Mrl/Pkn3tm1.1Mrl
Ptentm1Hwu/Ptentm1Hwu
Tg(Mx1-cre)1Cgn/0
involves: 129S4/SvJae * C57BL/6 * CBA/J
|
enlarged spleen |
J:216983
|
|
enlarged thymus |
J:216983
|
|
extramedullary hematopoiesis |
J:216983
|
|
increased acute lymphoblastic leukemia incidence |
J:216983
|
|
increased hemolymphoid system tumor incidence |
J:216983
|
|
premature death |
J:216983
|
Prkar1atm1.2Lsk/Prkar1a+
Ptentm1.1Mwst/Pten+
Tg(TPO-cre)1Shk/0
involves: 129S1/Sv * 129X1/SvJ * FVB/NCr
|
decreased survivor rate |
J:225245
|
|
normal
neoplasm |
J:225245
|
Prkar1atm1.2Lsk/Prkar1atm1.2Lsk
Ptentm1.1Mwst/Ptentm1.1Mwst
Tg(TPO-cre)1Shk/0
involves: 129S1/Sv * 129X1/SvJ * FVB/NCr
|
decreased abdominal adipose tissue amount |
J:225245
|
|
decreased subcutaneous adipose tissue amount |
J:225245
|
|
enlarged thyroid gland |
J:225245
|
|
increased activity of thyroid gland |
J:225245
|
|
increased circulating thyroxine level |
J:225245
|
|
increased metastatic potential |
J:225245
|
|
increased thyroid carcinoma incidence |
J:225245
|
|
premature death |
J:225245
|
|
weight loss |
J:225245
|
Ptentm1.1Hwu/Pten+
Tmprss2tm1.1(ERG)Sho/Tmprss2tm1.1(ERG)Sho
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
increased prostate intraepithelial neoplasia incidence |
J:212219
|
Ptentm1.1Hwu/Pten+
Tmprss2tm2.1(ETV1)Sho/Tmprss2tm2.1(ETV1)Sho
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
increased prostate intraepithelial neoplasia incidence |
J:212219
|
Ptentm1.1Mro/Pten+
Sdhbtm1.2Ics/Sdhb+
involves: 129S2/SvPas * BALB/c * C57BL/6
|
increased metastatic potential |
J:236514
|
|
increased pheochromocytoma incidence |
J:236514
|
Ptentm1.1Mwst/Ptentm1.1Mwst
Tg(MMTVneu)202Mul/0
Tg(S100a4-cre)1Gle/0
involves: FVB/N
|
increased mammary adenocarcinoma incidence |
J:153747
|
|
increased mammary gland tumor incidence |
J:153747
|
Ptentm1Hwu/Pten+
Tg(ARR2/Pbsn-FGF8)3Prb/0
Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2
|
enlarged prostate gland |
J:106650
|
|
increased metastatic potential |
J:106650
|
|
increased prostate gland adenocarcinoma incidence |
J:106650
|
|
increased prostate intraepithelial neoplasia incidence |
J:106650
|
|
prostate gland epithelial hyperplasia |
J:106650
|
Ptentm1Hwu/Pten+
Tmprss2tm2.1(ETV1)Sho/Tmprss2tm2.1(ETV1)Sho
Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
increased prostate gland adenocarcinoma incidence |
J:212219
|
|
premature death |
J:212219
|
|
prostate gland cyst |
J:212219
|
Ptentm1Hwu/Ptentm1Hwu
Cop1tm2.1Vmd/Cop1tm2.1Vmd
Tg(Pbsn-cre)4Prb/0
B6N.CgCop1tm2.1Vmd Ptentm1Hwu Tg(Pbsn-cre)4Prb
|
increased prostate gland adenocarcinoma incidence |
J:172653
|
|
increased prostate intraepithelial neoplasia incidence |
J:172653
|
Ptentm1Hwu/Ptentm1Hwu
Ptpn1tm1Bpk/Ptpn1tm1Bpk
Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * DBA/2
|
increased prostate gland adenocarcinoma incidence |
J:231906
|
|
increased prostate intraepithelial neoplasia incidence |
J:231906
|
Ptentm1Hwu/Ptentm1Hwu
Ptpn11tm1Gsf/Ptpn11tm1Gsf
Tg(Six3-cre)69Frty/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2
|
optic nerve atrophy |
J:174095
|
|
retina degeneration |
J:174095
|
|
retina ganglion cell degeneration |
J:174095
|
|
retina outer nuclear layer degeneration |
J:174095
|
|
thin retina ganglion layer |
J:174095
|
|
thin retina inner nuclear layer |
J:174095
|
|
thin retina outer nuclear layer |
J:174095
|
Ptentm1Hwu/Ptentm1Hwu
Rictortm1.1Mgn/Rictortm1.1Mgn
involves: 129S4/SvJae * 129S6/SvEvTac
|
abnormal prostate gland duct morphology |
J:144810
|
|
abnormal prostate gland epithelium morphology |
J:144810
|
|
decreased tumor incidence |
J:144810
|
Ptentm1Hwu/Ptentm1Hwu
Rictortm1.1Mgn/Rictortm1.1Mgn
Tg(Ins2-cre)25Mgn/0
involves: 129S4/SvJae * 129S6/SvEvTac * BALB/c * C57BL/6 * DBA
|
abnormal glucose homeostasis |
J:170129
|
|
abnormal pancreatic beta cell morphology |
J:170129
|
|
decreased circulating insulin level |
J:170129
|
|
decreased pancreatic beta cell mass |
J:170129
|
|
hypoglycemia |
J:170129
|
|
postnatal growth retardation |
J:170129
|
Ptentm1Hwu/Ptentm1Hwu
Rps6kb1tm1Gtho/Rps6kb1tm1Gtho
Tg(Mx1-cre)1Cgn/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA
|
enlarged spleen |
J:169097
|
|
enlarged thymus |
J:169097
|
|
increased acute lymphoblastic leukemia incidence |
J:169097
|
|
premature death |
J:169097
|
Ptentm1Hwu/Ptentm1Hwu
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Tg(Alb1-cre)1Dlr/0
involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N
|
abnormal bile duct morphology |
J:111718
|
|
enlarged liver |
J:111718
|
|
hepatic steatosis |
J:111718
|
|
increased cholangiocarcinoma incidence |
J:111718
|
|
increased liver weight |
J:111718
|
|
premature death |
J:111718
|
Ptentm1Hwu/Ptentm1Hwu
Tg(CAG-EGFP,-PAX8/PPARG)1Rkoe/0
Tg(TPO-cre)1Shk/0
involves: 129S4/SvJae * FVB/NCr * FVB/NJ
|
abnormal thymus physiology |
J:177181
|
|
abnormal thyroid gland morphology |
J:177181
|
|
enlarged thyroid gland |
J:177181
|
|
increased circulating thyroxine level |
J:177181
|
|
increased circulating triiodothyronine level |
J:177181
|
|
increased thyroid carcinoma incidence |
J:177181
|
Ptentm1Hwu/Ptentm1Hwu
Tg(CAG-fat-1)1Jxk/0
Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2
|
abnormal lipid homeostasis |
J:124208
|
|
decreased prostate gland weight |
J:124208
|
Ptentm1Hwu/Ptentm1Hwu
Tg(CAG-MYC,-GFP*)#Rugg/0
Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2
|
increased prostate gland adenocarcinoma incidence |
J:261540
|
|
increased prostate intraepithelial neoplasia incidence |
J:261540
|
|
premature death |
J:261540
|
Ptentm1Hwu/Ptentm1Hwu
Tg(Pdx1-cre)89.1Dam/0
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * CBA
|
increased pancreatic acinar cell carcinoma incidence |
J:102226
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:102226
|
Ptentm1Hwu/Ptentm1Hwu
Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl
Tg(KRT14-cre/ERT)20Efu/0
involves: 129 * 129S4/SvJae * C57BL/6 * CD-1 * FVB/N
|
abnormal anal canal morphology |
J:209026
|
|
increased oral papilloma incidence |
J:194652
|
|
increased organ/body region tumor incidence |
J:209026
|
|
increased papilloma incidence |
J:194652
|
|
increased squamous cell carcinoma incidence |
J:194652,
J:209026
|
Ptentm1Hwu/Ptentm1Hwu
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB
|
increased carcinoma incidence |
J:146760
|
|
increased urinary bladder carcinoma incidence |
J:146760
|
|
premature death |
J:146760
|
Ptentm1Hwu/Ptentm1Hwu
Trp53tm2Tyj/Trp53+
Amhr2tm3(cre)Bhr/Amhr2+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd
|
ascites |
J:222579
|
|
increased granulosa cell tumor incidence |
J:222579
|
|
increased metastatic potential |
J:222579
|
|
increased ovarian carcinoma incidence |
J:222579
|
|
premature death |
J:222579
|
Ptentm1Hwu/Ptentm1Hwu
Tsc1tm1Djk/Tsc1tm1Djk
Tg(Gdf9-icre)5092Coo/?
involves: 129S4/SvJae * C57BL/6J
|
abnormal ovarian follicle morphology |
J:155357
|
Ptentm1Hwu/Ptentm1Hwu
Vhltm1Jae/Vhltm1Jae
Tg(Cdh16-cre)91Igr/0
involves: 129S4/SvJae * BALB/c * C57BL/6J * ICR
|
abnormal kidney cortex morphology |
J:137073
|
|
abnormal kidney epithelium morphology |
J:137073
|
|
abnormal kidney pelvis urothelium morphology |
J:137073
|
|
abnormal renal tubule epithelial cell primary cilium morphology |
J:137073
|
|
hydronephrosis |
J:137073
|
|
increased kidney cell proliferation |
J:137073
|
|
increased kidney weight |
J:137073
|
|
kidney cortex cyst |
J:137073
|
|
kidney cyst |
J:137073
|
|
kidney medulla cyst |
J:137073
|
|
normal
neoplasm |
J:137073
|
Ptentm1Hwu/Ptentm1Hwu
Vhltm1Jae/Vhltm1Jae
Tg(Cdh16-cre)91Igr/0
involves: 129S4/SvJae * ICR
|
abnormal epididymis morphology |
J:137442
|
|
abnormal oviduct morphology |
J:137442
|
|
abnormal uterine cervix squamous epithelium morphology |
J:137442
|
|
endometrium hyperplasia |
J:137442
|
|
increased adenoma incidence |
J:137442
|
|
increased epididymal cystadenoma incidence |
J:137442
|
|
increased tumor incidence |
J:137442
|
Ptentm1Mro/Pten+
Sdhbtm1.1Ics/Sdhb+
Tg(KLK3-cre)D4Trp/0
involves: 129S2/SvPas * FVB
|
increased pheochromocytoma incidence |
J:236514
|
Ptentm1Mro/Ptentm1Mro
Sdhbtm1.1Ics/Sdhb+
Tg(KLK3-cre)D4Trp/0
involves: 129S2/SvPas * FVB
|
increased pheochromocytoma incidence |
J:236514
|
Ptentm1Mro/Ptentm1Mro
Sdhbtm1.1Ics/Sdhbtm1.2Ics
Tg(KLK3-cre)D4Trp/0
involves: 129S2/SvPas * BALB/c * C57BL/6 * FVB
|
increased pheochromocytoma incidence |
J:236514
|
Ptentm1Mro/Ptentm1Mro
Tg(KRT14-cre)8Brn/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * DBA/2J * FVB/N
|
increased carcinoma incidence |
J:144831
|
|
premature death |
J:144831
|
|
weakness |
J:144831
|
Ptentm1Ppp/Pten+
Rac1tm1Tyb/Rac1tm2Tyb
Edil3Tg(Sox2-cre)1Amc/Edil3+
involves: 129S/Sv * C3H * C57BL/6 * CBA
|
abnormal apoptosis |
J:173526
|
|
abnormal embryo development |
J:173526
|
Ptentm1Ppp/Pten+
Tg(Pbsn-TAg)15Tvd/0
involves: 129S1/Sv * C57BL/6 * DBA/2
|
abnormal prostate gland physiology |
J:103408
|
|
increased prostate gland adenocarcinoma incidence |
J:103408
|
|
increased prostate gland tumor incidence |
J:103408
|
|
increased prostate intraepithelial neoplasia incidence |
J:103408
|
Ptentm1Rdp/Pten+
Trp53tm1Brn/Trp53tm1Brn
Tg(GFAP-cre)25Mes/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N
|
ataxia |
J:140704
|
|
increased astrocytoma incidence |
J:140704
|
|
increased glioblastoma incidence |
J:140704
|
|
increased glioma incidence |
J:140704
|
|
paralysis |
J:140704
|
|
seizures |
J:140704
|
Ptentm1Rdp/Ptentm1Rdp
Smad4tm1Rdp/Smad4tm1Rdp
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
involves: 129 * C57BL/6 * DBA/2
|
increased metastatic potential |
J:186105
|
|
increased prostate gland adenocarcinoma incidence |
J:186105
|
|
premature death |
J:186105
|
Ptentm1Rdp/Ptentm1Rdp
Terttm1Rdp/Tert+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2
|
increased prostate gland adenocarcinoma incidence |
J:186105
|
|
increased prostate intraepithelial neoplasia incidence |
J:186105
|
|
premature death |
J:186105
|
Ptentm1Rdp/Ptentm1Rdp
Terttm1Rdp/Terttm1Rdp
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2
|
decreased telomere length |
J:186105
|
|
decreased tumor growth/size |
J:186105
|
|
increased prostate intraepithelial neoplasia incidence |
J:186105
|
Ptentm1Rdp/Ptentm1Rdp
Terttm3Rdp/Terttm3Rdp
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2
|
abnormal chromosome morphology |
J:186105
|
|
decreased tumor-free survival time |
J:186105
|
|
increased metastatic potential |
J:186105
|
|
increased prostate gland adenocarcinoma incidence |
J:186105
|
|
increased prostate intraepithelial neoplasia incidence |
J:186105
|
|
increased telomere length |
J:186105
|
Ptentm1Rdp/Ptentm1Rdp
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2
|
increased prostate gland adenocarcinoma incidence |
J:186105
|
|
increased prostate intraepithelial neoplasia incidence |
J:186105
|
|
premature death |
J:186105
|
Ptentm1Rps/Pten+
Tg(Wnt1)1Hev/0
involves: 129S1/Sv * C57BL/6 * FVB/N * SJL
|
increased adenocarcinoma incidence |
J:67497
|
|
increased mammary adenocarcinoma incidence |
J:67497
|
|
increased mammary gland ductal carcinoma incidence |
J:67497
|
|
increased metastatic potential |
J:67497
|
|
increased salivary adenocarcinoma incidence |
J:67497
|
Ptentm1Rps/Pten+
Slc6a4tm1Kpl/Slc6a4+
B6.129-Slc6a4tm1Kpl Ptentm1Rps
|
abnormal social investigation |
J:144937
|
|
decreased prepulse inhibition |
J:144937
|
|
increased brain weight |
J:144937
|
|
megacephaly |
J:144937
|
|
reduced sensorimotor gating |
J:144937
|
Ptentm1Rps/Pten+
Rptortm1Lex/Rptor+
involves: 129S/SvEvBrd * 129S1/Sv * C57BL/6
|
normal
mortality/aging |
J:144810
|
Ptentm1Rps/Pten+
RictorGt(RRR347)Byg/Rictor+
involves: 129P2/OlaHsd * 129S1/Sv * BALB/c * C57BL/6
|
decreased tumor incidence |
J:144810
|
|
extended life span |
J:144810
|
|
prostate gland hyperplasia |
J:144810
|
Ptentm2.1Ppp/Pten+
Spry1tm1Jdli/Spry1tm1.1Jdli
Spry2tm1Mrt/Spry2tm1.1Mrt
Tg(Osr1-cre)4Mrt/0
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N
|
increased prostate gland tumor incidence |
J:192348
|
|
increased prostate intraepithelial neoplasia incidence |
J:192348
|
Ptentm2.1Ppp/Pten+
Tg(Cnp-EGFR)10Nrat/0
Tg(Dhh-cre)1Mejr/0
involves: 129S1/Sv * C57BL/6 * FVB/N * SJL
|
abnormal nervous system morphology |
J:195067
|
|
abnormal sciatic nerve morphology |
J:195067
|
|
abnormal trigeminal nerve morphology |
J:195067
|
|
increased neurofibrosarcoma incidence |
J:195067
|
Ptentm2.1Ppp/Ptentm2.1Ppp
Rb1tm2Brn/Rb1tm2Brn
Tg(Pbsn-cre)4Prb/0
involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2
|
increased prostate intraepithelial neoplasia incidence |
J:307910
|
|
premature death |
J:307910
|
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(CAG-Bgeo,-Spry2,-ALPP)1Mrt/0
Tg(Osr1-cre)4Mrt/0
involves: 129P2/OlaHsd * 129S1/Sv * FVB/N
|
increased prostate intraepithelial neoplasia incidence |
J:192348
|
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Cnp-EGFR)10Nrat/0
Tg(Dhh-cre)1Mejr/0
involves: 129S1/Sv * C57BL/6 * FVB/N * SJL
|
abnormal nervous system morphology |
J:195067
|
|
abnormal sciatic nerve morphology |
J:195067
|
|
abnormal trigeminal nerve morphology |
J:195067
|
|
enlarged dorsal root ganglion |
J:195067
|
|
increased neurofibrosarcoma incidence |
J:195067
|
|
premature death |
J:195067
|
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(GFAP-TAg121)1Tvd/0
involves: 129S1/Sv * C57BL/6 * C57BL/6J * DBA/2 * FVB/N
|
abnormal astrocyte apoptosis |
J:99385
|
|
abnormal brain vasculature morphology |
J:99385
|
|
increased angiogenesis |
J:99385
|
|
increased astrocytoma incidence |
J:99385
|
Ptentm2.1Ppp/Ptentm2.1Ppp
Trp53tm1Brn/Trp53tm1Brn
Tg(TPO-cre)1Shk/0
129.Cg-Tg(TPO-cre)1Shk Trp53tm1Brn Ptentm2.1Ppp
|
decreased thyroid-stimulating hormone level |
J:211100
|
|
enlarged thyroid gland |
J:211100
|
|
increased metastatic potential |
J:211100
|
|
increased thyroid carcinoma incidence |
J:211100
|
|
premature death |
J:211100
|
Ptentm2.1Ppp/Ptentm2.1Ppp
Trp53tm1Thl/Trp53tm1Thl
Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * C57BL/6 * DBA/2
|
increased carcinoma incidence |
J:100683
|
|
increased prostate gland tumor incidence |
J:100683
|
|
kidney failure |
J:100683
|
|
premature death |
J:100683
|
|
urinary bladder obstruction |
J:100683
|
Ptentm2Mak/Ptentm2Mak
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Tg(KRT5-cre)1Xya/0
involves: 129P2/OlaHsd * 129S6/SvEvTac
|
abnormal hair follicle regression |
J:101602
|
|
alopecia |
J:101602
|
|
decreased tumor latency |
J:101602
|
|
epithelioid cyst |
J:101602
|
|
increased carcinoma incidence |
J:101602
|
|
increased hair follicle cell proliferation |
J:101602
|
|
increased keratinocyte proliferation |
J:101602
|
|
increased skin papilloma incidence |
J:101602
|
|
increased skin tumor incidence |
J:101602
|
|
increased stomach tumor incidence |
J:101602
|
|
premature death |
J:101602
|
|
thick epidermis |
J:101602
|
|
thick hair follicle outer root sheath |
J:101602
|
Ptentm2Mak/Ptentm2Mak
Stk11tm1Keis/Stk11tm1Keis
Tg(Cyp1a1-cre/ERT)1Dwi/0
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * CBA
|
abnormal urinary bladder mucosa morphology |
J:169565
|
|
abnormal urinary bladder urothelium morphology |
J:169565
|
|
enlarged urinary bladder |
J:169565
|
|
increased urinary bladder carcinoma incidence |
J:169565
|
|
premature death |
J:169565
|
|
urinary bladder obstruction |
J:169565
|
Ptentm2Mak/Ptentm2Mak
Tg(Ckmm-cre)5Khn/0
Tg(Myh6-Pik3ca)1Siz/0
involves: 129P2/OlaHsd * FVB
|
decreased cardiac muscle contractility |
J:79151
|
|
small heart |
J:79151
|
Ptentm2Mak/Ptentm2Mak
Tg(GFAP-cre/Esr1*,-lacZ)ASbk/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * FVB/NJ
|
increased glioblastoma incidence |
J:290447
|
|
premature death |
J:290447
|
Ptentm2Mak/Ptentm2Mak
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Tfln/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N
|
increased mammary adenocarcinoma incidence |
J:224955
|
|
increased mammary gland tumor incidence |
J:224955
|
|
increased myoepithelioma incidence |
J:224955
|
|
increased spindle cell carcinoma incidence |
J:224955
|
Ptentm2Mak/Ptentm2Mak
Trp53tm1Brn/Trp53tm1Brn
Tg(Nes-cre/ERT2,-ALPP)1Sbk/0
involves: 129P2/OlaHsd
|
abnormal cerebellum morphology |
J:237990
|
|
increased glioma incidence |
J:237990
|
|
increased medulloblastoma incidence |
J:237990
|
Ptentm2Mak/Ptentm2Mak
Trp53tm1Brn/Trp53tm1Brn
Tg(Wap-cre)11738Mam/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL
|
increased mammary adenocarcinoma incidence |
J:224955
|
|
increased mammary gland tumor incidence |
J:224955
|
|
increased myoepithelioma incidence |
J:224955
|
|
increased spindle cell carcinoma incidence |
J:224955
|
Tg(Pten)1Srn/0
involves: C57BL/6 * CBA
|
abnormal adipose tissue morphology |
J:182671
|
|
abnormal brown adipose tissue morphology |
J:182671
|
|
abnormal brown adipose tissue physiology |
J:182671
|
|
abnormal cell physiology |
J:182671
|
|
abnormal excitatory postsynaptic potential |
J:234430
|
|
decreased body fat mass |
J:182671
|
|
decreased body weight |
J:182671
|
|
decreased brown fat cell lipid droplet size |
J:182671
|
|
decreased cell proliferation |
J:182671
|
|
decreased circulating cholesterol level |
J:182671
|
|
decreased circulating insulin level |
J:182671
|
|
decreased circulating insulin-like growth factor I level |
J:182671
|
|
decreased circulating leptin level |
J:182671
|
|
decreased embryo size |
J:182671
|
|
decreased epididymal fat pad weight |
J:182671
|
|
decreased fasting circulating glucose level |
J:182671
|
|
decreased incidence of tumors by chemical induction |
J:182671
|
|
decreased susceptibility to diet-induced hepatic steatosis |
J:182671
|
|
decreased white fat cell size |
J:182671
|
|
enhanced coordination |
J:182671
|
|
extended life span |
J:182671
|
|
increased adipocyte glucose uptake |
J:182671
|
|
increased basal metabolism |
J:182671
|
|
increased energy expenditure |
J:182671
|
|
increased insulin sensitivity |
J:182671
|
|
polyphagia |
J:182671
|
|
postnatal lethality, incomplete penetrance |
J:182671
|
Ube2otm1.1(KOMP)Mbp/Ube2otm1.1(KOMP)Mbp
Ptentm1Ppp/Ptentm1Ppp
involves: 129S1/Sv * C57BL/6 * C57BL/6N * FVB/N
|
increased lymphoma incidence |
J:239679
|
Excel File
Analysis Tools